A Crossover Study to Evaluate Pegilodecakin (LY3500518) in Healthy Participants

Exclusion Criteria

• •Pregnant or lactating subjects
• •Have previously participated in an investigational trial involving administration of any investigational compound within 30 days prior to the study dosing
• •Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance
• •Have smoked or used tobacco/nicotine products within 90 days prior to the study dosing
• •Have been treated with systemic steroids, immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents during the study (e.g., corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)
• •Have been vaccinated within 90 days of study dosing